Current views on the possible involvement of aluminum in the etiology of Alzheimer's disease

Cover Page

Cite item

Full Text

Abstract

The aim of the study was to investigate the possibility of using а concentration of aluminum as a marker of neurodegenerative diseases.

Material and methods. To achieve this goal, there was carried out an analysis of literary origins from various databases, in particular Scopus and PubMed.

Results. The analysis shows that by now there has been accumulated strong evidence that certain neurodegenerative diseases are associated with chronic exposure to low-dose of aluminum: in particular, Alzheimer's disease (AD); motor neuron disease or amyotrophic lateral sclerosis (ALS); multiple sclerosis (MS) and a number of others.

Conclusion. Thus, it can be assumed that the measurement of the concentration of Al in the blood plasma will make it possible to identify a group people with of high risk of AD, which will allow starting preventive treatment at the earliest stage of the disease. The capabilities of the existing methods of analysis: atomic absorption spectrometry with electrothermal atomization (GFAAS) and inductively coupled plasma mass spectrometry (ICP-MS) enable to solve this problem.

About the authors

N. B. Ivanenko

Golikov Research Center of Toxicology of the Federal Medical and Biological Agency

Author for correspondence.
Email: nbivanenko@mail.ru

Natalya B. Ivanenko - PhD in Chemistry Sciences, Leading Researcher at the Laboratory of Toxicological Chemistry of Inorganic Compounds of the Golikov Research Center of Toxicology of the FMBA of Russian Federation.

192019, Saint-Petersburg.

Russian Federation

A. A. Ganeev

Golikov Research Center of Toxicology of the Federal Medical and Biological Agency

Email: ganeev@lumex.ru

Aleksandr A. Ganeev.

192019, Saint Petersburg.

Russian Federation

E. A. Zubakina

Golikov Research Center of Toxicology of the Federal Medical and Biological Agency

Email: mihailova_katya@inbox.ru

Еkaterina А. Zubakina.

192019, Saint Petersburg.

Russian Federation

M. M. Bezruchko

Golikov Research Center of Toxicology of the Federal Medical and Biological Agency

Email: bezrucko@mail.ru

Мarina М. Bezruchko.

192019, Saint Petersburg.

Russian Federation

A. R. Gubal

Saint Petersburg State University, Institute of Chemistry

Email: a.r.gubal@mail.ru

Anna R. Gubal.

199034, Saint Petersburg.

Russian Federation

V. A. Chuchina

Saint Petersburg State University, Institute of Chemistry

Email: vikky95bodnar@gmail.com

Viktoriya А. Chuchina.

199034, Saint Petersburg.

Russian Federation

B. S. Litvintsev

Golikov Research Center of Toxicology of the Federal Medical and Biological Agency

Email: litvintsevs@yandex.ru

Bogdan S. Litvintsev.

192019, Saint Petersburg.

Russian Federation

References

  1. Campbell A. The potential role of aluminium in Alzheimer's disease. Nephrology 29. Dialysis Transplantation. 2002; 17 (2):17-20.
  2. McLachlan D.R. Aluminium and the risk for Alzheimer's disease. Environmetrics. 1995; 6 (3): 233-75.
  3. Zatta P., Kiss T., Suwalsky M., Berthon G. Aluminium (III) as a promoter of cellular oxidation. Coordination Chemistry Reviews. 2002; 228 (2): 271-84.
  4. Suwalsky M., Norris B., Kiss T., Zatta P. Effects of Al(III) speciation on cell membranes and molecular models. Coordination Chemistry Reviews. 2002; 228 (2): 285-95.
  5. Kawahara M. Effects of aluminum on the nervous systemand its possible link with neurodegenerative diseases. Journal of Alzheimer's Disease. 2005; 8 (2): 171-82.
  6. Zatta P., Lucchini R., van Rensburg S.J., Taylor A. The role of metals in neurodegenerative processes: aluminum, manganese, and zinc. Brain Research Bulletin. 2003; 62: 15-28.
  7. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron. 1991; 6 (4): 487-98.
  8. Klatzo I., Wisniewski H., Streicher E. Experimental production of neurofibrillary 34. degeneration I. Light microscopic observation. Journal of Neuropathology & Experimental Neurology. 1965; 24: 187-99.
  9. Crapper D.R., Krishnan S.S., Dalton A. J. Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Science. 1973; 180 (4085): 511-3.
  10. Martyn C.N., Osmond C., Edwardson J.A., Barker D.J.P., Harris E.C., Lacey R.F. Geographical relation between Alzheimer's disease and aluminium in drinking water. The Lancet. 1989; 1 (8629): 59-62.
  11. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297 (5580): 353-6.
  12. Wirths O., Multhaup G., Bayer T.A. A modified в- amyloid hypothesis: intraneuronal accumulation of the в-amyloid peptide - the first step of a fatal cascade. Journal of Neurochemistry. 2004; 91(3): 513-20.
  13. Sensi S.L., Paoletti P., Bush A.I., Sekler I. Zinc in the physiology and pathology of the CNS. Nature Reviews Neuroscience. 2009; 10(11): 780-91.
  14. Zatta P., Drago D., Bolognin S., Sensi S. L. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends in Pharmacological Sciences. 2009; 30 (7): 346-55.
  15. Hung Y.H., Bush A.I., Cherny R.A. Copper in the brain and Alzheimer's disease. Journal of Biological Inorganic Chemistry. 2010; 15 (1): 61-76.
  16. Bush A.I., Pettingell W.H., Multhaup G., et al. Rapid induction of Alzheimer Ав amyloid formation by zinc. Science. 1994; 265 (5177): 1464-7.
  17. Atwood C.S., Moir R.D., Huang X., et al. Dramatic aggregation of alzheimer Ав by Cu(II) is induced by conditions representing physiological acidosis. Journal of Biological Chemistry. 1998; 273 (21): 12817-26.
  18. Lovell M.A., Xie C., Markesbery W.R. Protection against amyloid beta peptide toxicity by zinc. Brain Research. 1999; 823 (1-2): 88-95.
  19. Kawahara M., Arispe N., Kuroda Y., Rojas E. Alzheimer's disease amyloid в-protein forms Zn2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophysical Journal. 1997; 73 (1): 67-75.
  20. Bjertness E., Candy J.M., Torvik A. et al. Content of brain aluminum is not elevated in Alzheimer disease. Alzheimer Disease and Associated Disorders. 1996; 10 (3): 171-4.
  21. Landsberg J. P., McDonald B., Watt F. Absence of aluminium in neuritic plaque cores in Alzheimer's disease. Nature. 1992; 360 (6399): 65-68.
  22. Bouras C., Giannakopoulos P., Good P. F., Hsu A., Hof P. R., Perl D. P. A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. European Neurology. 1997; 38 (1): 53-8.
  23. Candy J. M., McArthur F. K., Oakley A. E. et al. Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. Journal of the Neurological Sciences. 1992; 107 (2): 210-28.
  24. Yumoto S., Kakimi S., Ohsaki A., Ishikawa A. Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease. Journal of Inorganic Biochemistry. 2009; 103 (11): 1579-84.
  25. Parhad I.M., Krekoski C.A., Mathew A., Tran P. M. Neuronal gene expression in aluminum myelopathy. Cellular and Molecular Neurobiology. 1989; 9 (1): 123-38.
  26. Lukiw W.J., LeBlanc H.J., Carver L.A., McLachlan D.R. C., Bazan N.G. Run-on gene transcription in human neocortical nuclei: inhibition by nanomolar aluminum and implications for neurodegenerative disease. Journal of Molecular Neuroscience. 1998; 11 (1): 67-78.
  27. Kawahara M., Konoha K., Nagata T., Sadakane Y. Aluminum and human health: its intake, bioavailability and neurotoxicity. Biomedical Research on Trace Elements. 2007; 18: 111-20.
  28. Yumoto S., Nagai H., Kobayashi K., Tamate A., Kakimi S., Matsuzaki H. Al incorporation into the brain of suckling rats through maternal milk. Journal of Inorganic Biochemistry. 2003; 97 (1): 155-60.
  29. Priest N.D. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. Journal of Environmental Monitoring. 2004; 6 (5): 375-403.
  30. Kawahara M. Aluminum and human health: possible link with neurodegenerative disorders. In: S. Huang Ed. Metals and Neurodegeneration. Research Signpost. 2010.
  31. Rondeau V., Jacqmin-Gadda H., Commenges D., et al. Re: aluminum in drinking water and cognitive decline in elderly subjects: the PAQUID cohort [letter]. Am J Epidemiol. 2001; 154(3): 288-90.
  32. Gauthier E., Fortier I., Courchesne F., et al. Aluminum forms in drinking water and risk of Alzheimer's disease. Environ Res. 2000; 84(3): 234-46.
  33. Rondeau V., Jacqmin-Gadda H., Commenges D., Helmer C., Dartigues J.F. Aluminum and Silica in Drinking Water and the Risk of Alzheimer's Disease or Cognitive Decline: Findings From 15-Year Follow-up of the PAQUID Cohort. American Journal of Epidemiology. 2009; 169 (4): 489-96.
  34. Yokel R.A, Florence R.L. Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. Toxicology. 2006; 227(1-2):86-93.
  35. Altmann P., Cunningham J., Dhanesha U., Ballard M., Thompson J., Marsh F. Disturbance of cerebral function in people exposed to drinking water contaminated with aluminium sulphate: retrospective study of the Camelfordwater incident. British Medical Journal. 1999; 319 (7213): 807-11.
  36. Flaten T.P. Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain Research Bulletin. 2001; 55 (2): 187-96.
  37. Darbre P.D. Aluminium and the human breast. Morphologie. 2016; 100 (329): 65-74.
  38. Russo, L.S., Beale, G., Sandroni, S., Ballinger, W.E. Aluminum intoxication in undialysed adults with chronic renal failure. J. Neurol. Neurosurg. Psychiatry. 1992; 155: 697-700.
  39. Altmann P., Al-Salihi F., Butter K., Cutler P., Blair J., Leeming R., Cunningham J., Marsh F. Serum aluminum levels and erythrocyte dihydropteridine reductase activity in patients on hemodialysis. N. Engl. J. Med. 1987; 317: 80-4.
  40. Exley C., Esiri M.M. Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK. J Neurol Neuro-surg Psychiatry. 2006; 77: 877-9.
  41. Mirza A., King A., Troakes C., Exley C. Aluminium in brain tissue in familial Alzheimer's disease. Journal of Trace Elements in Medicine and Biology. 2017; 40: 30-6.
  42. Sjogren B., Elinder C.G., Lidums V., Chang G. Uptake and urinary excretion of aluminium among welders. Int Arch Occup Environ Health. 1988; 60 (2): 77-9.
  43. Sjogren B., Lidums V., Hakansson M., Hedstrom L. Exposure and urinary excretion of aluminium during welding. Scand J Work Environ Health. 1985; 11 (1): 39-43.
  44. Godderis L., Vanderheyden W., Van Geel J., Moens G., Masschelein R., Veulemans H. Exposure and inhalation risk assessment in an aluminium cast-house. J. Environ Monit. 2005; 7 (12): 1359-63.
  45. Guillard O., Fauconneau B., Olichon D., Dedieu G., Deloncle R. Hyperaluminemia in a woman using an aluminium-containing antiperspirant for 4 years. Am J Med. 2004; 117 (12): 956-9.
  46. Drobyshev E.J., Solovyev N.D., Gorokhovskiy B.M., Kashuro V.A. Accumulation Patterns of Sub-chronic Aluminum Toxicity Model After Gastrointestinal Administration in Rats. Biological Trace Element Research. 2018; 185: 384-94.
  47. Michalke B., Willkommen D., Drobyshev E., Solovyev N. The importance of speciation analysis in neurodegeneration research. TrAC -Trends Analytical Chemistry. 2018; 104: 160-70.
  48. Goulle' J.-P, Mahieu L., Castermant J., Neveu N., Bonneau L., Laine G., Bouige D., Lacroix F.C. Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair, Reference values. Forensic Science International. 2005; 153: 39-44.
  49. Скальный А.В. Химические элементы в физиологии и экологии человека. М.: Мир; 2004.
  50. D'Ilio S., Violante N., Di Gregorio M., Senofonte O., Petrucci F. Simultaneous quantification of 17 trace elements in blood by dynamic reaction cell inductively coupled plasma mass spectrometry (DRC-ICP-MS) equipped with a high-efficiency sample introduction system. Anal. Chim. Acta. 2006; 579: 202-8.
  51. Bocca B., Forte G., Petrucci F., Senofonte O., Violante N., Alimonti A. Development of methods for the quantification of essential and toxic elements in human biomonitoring. Ann 1st Super Sanita. 2005; 41 (2): 165-70.
  52. Magalhres C.G., Alves Lelis K.L., Aparecida Rocha C., Borba da Silva J.B. Direct determination of aluminium in serum and urine by electrothermal atomic absorption spectrometry using ruthenium as permanent modifier. Anal. Chim. Acta. 2002; 464 (2): 323-30.
  53. Иваненко Н.Б., Иваненко А.А., Соловьев Н.Д., Наволоцкий Д.В., Павлова О.В., Ганеев А.А. Определение Al, Be, Cd, Co, Cr, Mn, Ni, Pb, Se и Tl в цельной крови без предварительного разложения методом атомно-абсорбционной спектрометрии. Биомедицинская химия. 2014; 60 (3): 378-88.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Ivanenko N.B., Ganeev A.A., Zubakina E.A., Bezruchko M.M., Gubal A.R., Chuchina V.A., Litvintsev B.S.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.